DPP4 was identified as a marker for activated fibroblasts in systemic sclerosis [13], and inhibition of DPP4 limits ECM deposition and fibrosis in heart, lungs, liver and kidneys [[14], [15], [16], [17], [18], [19]], suggesting an active contribution to fibrosis. This evidence concerns the gene DPP4 and systemic sclerosis.